{"id":462186,"date":"2010-03-23T09:51:33","date_gmt":"2010-03-23T13:51:33","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=69848"},"modified":"2010-03-23T09:51:33","modified_gmt":"2010-03-23T13:51:33","slug":"alnylam-gets-20m-from-takeda","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/462186","title":{"rendered":"Alnylam Gets $20M From Takeda"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/rna-interference\/\">RNA Interference<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=ALNY\">ALNY<\/a>) <a href=\"http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=148005&amp;p=irol-newsArticle2&amp;ID=1404768&amp;highlight=\">said today<\/a> it has earned a $20 million milestone payment from Japan-based Takeda Pharmaceuticals for handing over certain RNA interference documents, materials and know-how. The payment is part of the partnership between the two companies, first formed in May 2008, which could be worth more than $1 billion over time. Alnylam is eligible to receive more milestones and royalties if Takeda translates the technology into RNAi products.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/boston\/2010\/03\/23\/alnylam-gets-20m-from-takeda-2\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Alnylam%20Gets%20$20M%20From%20Takeda%20http:\/\/xconomy.com\/?p=69848\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/boston\/2010\/03\/23\/alnylam-gets-20m-from-takeda-2\/&#038;t=Alnylam%20Gets%20$20M%20From%20Takeda\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/boston\/2010\/03\/23\/alnylam-gets-20m-from-takeda-2\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Alnylam+Gets+%2420M+From+Takeda&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fboston%2F2010%2F03%2F23%2Falnylam-gets-20m-from-takeda-2%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=d8d3a157eda3dd4eeee45b7640a67bc8&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=d8d3a157eda3dd4eeee45b7640a67bc8&#038;p=1\"\/><\/a><br \/>\n<!-- foo --><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/M0GUNovy0HA7xDqhPQW6tnMZ7MU\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/M0GUNovy0HA7xDqhPQW6tnMZ7MU\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/M0GUNovy0HA7xDqhPQW6tnMZ7MU\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/M0GUNovy0HA7xDqhPQW6tnMZ7MU\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/L8S9t2LXJ_A\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, RNA Interference, deals Luke Timmerman wrote: Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) said today it has earned a $20 million milestone payment from Japan-based Takeda Pharmaceuticals for handing over certain RNA interference documents, materials and know-how. The payment is part of the partnership between the two companies, first formed in May 2008, which could [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-462186","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/462186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=462186"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/462186\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=462186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=462186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=462186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}